AstraZeneca recently announced that Imfinzi combined with standard-of-care chemotherapy significantly improved overall survival and progression-free survival in patients with advanced biliary tract...
The National Institutes of Health (NIH) recently launched the first phase of Neuromod Prize, a $9.8 million competition to accelerate the development of neuromodulation therapies.
Neuromodulation...
Moderna and Carisma Therapeutics recently entered into an agreement to discover, develop, and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) cancer...
Cosette Pharmaceuticals recently acquired US sales and distribution rights to eight prescription medications from Daiichi Sankyo Company and its affiliates.
Under the 30-month transition agreement,...
AstraZeneca recently collaborated with Scorpion Therapeutics to discover, develop, and commercialize precision medicines against previously undruggable targets.
The companies will focus on a class of...
Bristol Myers Squibb and Century Therapeutics recently collaborated to develop and commercialize up to four engineered natural killer (iNK) and/or allogeneic cell therapies for hematologic malignancies...
Johnson & Johnson Medical Device Companies (JJMDC) recently tapped Microsoft to expand its secure and compliant digital surgery ecosystem.
Microsoft Cloud will help JJDMC drive innovation that...
Pfizer and Biohaven recently completed a collaboration transaction to commercialize small molecule migraine drugs, rimegepant and zavegepant, outside the US.
Rimegepant, commercialized as Nurtex ODT...
Pfizer and Acuitas Therapeutics recently entered into a development and option agreement under which Pfizer will license Acuitas’ lipid nanoparticle (LNP) technology for up to 10 mRNA vaccine or...
Sanofi and Exscientia recently entered into a research collaboration and license agreement to develop 15 novel small molecule drug candidates across oncology and immunology.
The companies will...
Eli Lilly & Company recently acquired exclusive rights to Entos Pharmaceuticals’ Fusogenix nucleic acid delivery technology to develop nucleic acid products.
The companies will initially...
Moderna recently dosed the first participant in a Phase 1 study of its mRNA vaccine, mRNA-1189, for Epstein-Barr Virus (EBV).
The Eclipse study will enroll nearly 270 participants 18 to 30 years of...
Novartis and Alnylam recently collaborated to leverage proprietary siRNA technology to develop liver-targeted therapy as an alternative to transplantation for patients experiencing liver...
Thermo Fisher Scientific recently completed the $1.85 billion acquisition of PeproTech to increase its capabilities in the high growth cell and gene therapy market.
PeproTech is a privately held...
FDA recently approved two pediatric indications for Johnson & Johnson’s direct oral anticoagulant (DOAC), Xarelto.
The agency approved the drug to treat venous thromboembolism (VTE) and to...
Life Science Biosensor Diagnostics (LSBD), a subsidiary of the iQ Group Global, recently filed an FDA Breakthrough Device Designation application for its Saliva Glucose Biosensor for diabetes care...
Biogen recently announced that it will reduce the wholesale acquisition cost (WAC) of its Alzheimer’s disease treatment, Aduhelm, in the US by nearly 50 percent.
For a patient of average weight,...
FDA recently sent a warning letter to Medtronic for the headquarters facility of its diabetes business in Northridge, California.
The warning letter focused on the inadequacy of specific medical...
Hackensack Meridian Health recently announced its support of the clinical development of a highly-differentiated immuno-oncology platform from Alloplex Biotherapeutics.
This investment is...
FDA recently approved ViiV Healthcare’s long-acting injectable pre-exposure prophylaxis (PrEP) treatment, Apretude, to reduce the risk of sexually acquired HIV-1.
The agency approved Apretude...
